Literature DB >> 21274559

The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Simon Schimmack1, Bernhard Svejda, Benjamin Lawrence, Mark Kidd, Irvin M Modlin.   

Abstract

BACKGROUND: Recent data demonstrate that the incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased exponentially (overall ~500%) over the last three decades, thus refuting the erroneous concept of rarity. GEP-NETs comprise 2% of all malignancies and in terms of prevalence, are the second commonest gastrointestinal malignancy after colorectal cancer. Diagnosis is usually late since there is no biochemical screening test and symptoms are protean and overlooked. As a consequence, 60-80% exhibit metastases with a consequent suboptimal outcome. DISCUSSION: The gastrointestinal tract and pancreas exhibit ~17 different neuroendocrine cell types, but neither the cell of origin nor the biological basis of GEP-NETs is understood. This review examines GEP-NETs from the cellular and molecular perspective and addresses the distinct patterns of functional tumor biology pertinent to clinicians. Although grouped as a neoplastic entity (NETs), each lesion is derived from distinct cell precursors, produces specific bioactive products, exhibits distinct chromosomal abnormalities and somatic mutation events and has uniquely dissimilar clinical presentations. GEP-NETs demonstrate very different survival rates reflecting the intrinsic differences in malignant potential and variations in proliferative regulation. Apart from the identification of the inhibitory role of the somatostatin receptors, there is limited biological knowledge of the key regulators of proliferation and hence a paucity of successful targeted therapeutic agents. IGF-I, TGFβ and a variety of tyrosine kinases have been postulated as key regulatory elements; rigorous data is still required to define predictably effective and rational therapeutic strategy in an individual tumor. A critical issue in the clinical management of GEP-NETs is the need to appreciate both the neuroendocrine commonalities of the disease as well as the unique characteristics of each tumor. The further acquisition of a detailed biological and molecular appreciation of GEP-NETs is vital to the development of effective management strategy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21274559     DOI: 10.1007/s00423-011-0739-1

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  197 in total

1.  Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden.

Authors:  K Hemminki; X Li
Journal:  Int J Cancer       Date:  2001-11-01       Impact factor: 7.396

2.  Prognostic and immunohistochemical validation of the capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases.

Authors:  M F Heymann; M Joubert; J Nemeth; B Franc; J Visset; A Hamy; J le Borgne; J C le Neel; A Murat; S Cordel; M F le Bodic
Journal:  Histopathology       Date:  2000-05       Impact factor: 5.087

3.  A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum.

Authors:  Kyle M Walsh; Murim Choi; Kjell Oberg; Matthew H Kulke; James C Yao; Chengqing Wu; Magdalena Jurkiewicz; Ling-I Hsu; Susanne M Hooshmand; Manal Hassan; Eva T Janson; Janet L Cunningham; Evan Vosburgh; Richard S Sackler; Richard P Lifton; Andrew T Dewan; Josephine Hoh
Journal:  Endocr Relat Cancer       Date:  2011-01-13       Impact factor: 5.678

4.  Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence?

Authors:  B Helpap; J Köllermann
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

5.  Carcinoid tumors of the gastrointestinal tract: a 44-year experience.

Authors:  S Saha; S Hoda; R Godfrey; C Sutherland; K Raybon
Journal:  South Med J       Date:  1989-12       Impact factor: 0.954

6.  Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases.

Authors:  C Bordi; J Y Yu; M T Baggi; C Davoli; F P Pilato; G Baruzzi; G Gardini; G Zamboni; G Franzin; M Papotti
Journal:  Cancer       Date:  1991-02-01       Impact factor: 6.860

7.  A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients.

Authors:  Christine S Landry; Guy Brock; Charles R Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  Ann Surg Oncol       Date:  2008-10-24       Impact factor: 5.344

8.  Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1.

Authors:  Mark Kidd; Irvin M Modlin; Roswitha Pfragner; Geeta N Eick; Manish C Champaneria; Anthony K Chan; Robert L Camp; Shrikant M Mane
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

9.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

10.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

View more
  58 in total

Review 1.  EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets.

Authors:  M Kidd; S Schimmack; B Lawrence; D Alaimo; I M Modlin
Journal:  Neuroendocrinology       Date:  2012-06-15       Impact factor: 4.914

2.  Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.

Authors:  Simon Schimmack; Andrew Taylor; Ben Lawrence; Hubertus Schmitz-Winnenthal; Lars Fischer; Markus W Büchler; Irvin M Modlin; Mark Kidd; Laura H Tang
Journal:  Tumour Biol       Date:  2014-09-30

3.  CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?

Authors:  Yanji Luo; Jie Chen; Bingqi Shen; Meng Wang; Huasong Cai; Ling Xu; Luohai Chen; Minhu Chen; Zi-Ping Li; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2018-06-06       Impact factor: 5.315

4.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

Review 5.  Current state of knowledge on neuroendocrine small bowel tumours: non-systematic review of the literature based on one case.

Authors:  Nicolae Irinel Simion; Valentin Muntean; Ovidiu Fabian
Journal:  BMJ Case Rep       Date:  2013-01-17

6.  Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.

Authors:  Sarah Wulfert; Clemens Kratochwil; Peter L Choyke; Ali Afshar-Oromieh; Walter Mier; Hans-Ulrich Kauczor; Jens-Peter Schenk; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

7.  Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies.

Authors:  Stefano Bacchetti; Enrico Maria Pasqual; Serena Bertozzi; Ambrogio P Londero; Andrea Risaliti
Journal:  Gland Surg       Date:  2014-11

8.  Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptor.

Authors:  Alessia Di Florio; Veronica Sancho; Paola Moreno; Gianfranco Delle Fave; Robert T Jensen
Journal:  Biochim Biophys Acta       Date:  2012-12-04

Review 9.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

10.  Imaging in neuroendocrine tumors: an update for the clinician.

Authors:  Jessica E Maxwell; James R Howe
Journal:  Int J Endocr Oncol       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.